NCL News Archive

Monday, July 10, 2017

New Drug Release Protocol Available

The NCL has just added a new protocol to our Assay Cascade Protocols page to measure drug release from nanomedicines. The protocol, PHA-2, is based off of the recent Journal of Controlled Release publication, Stable isotope method to measure drug release from nanomedicines. Since its publication in late 2015, this assay has gained a lot of attention and has been in high demand at the NCL,... View Post


Monday, July 10, 2017

Inaugural FNLCR Technology Showcase Draws Hundreds

More than 200 science and business professionals from across the region attended the Frederick National Laboratory for Cancer Research’s (FNLCR) Inaugural Technology Showcase event. The program highlighted technologies developed by NCI and FNLCR investigators available for license or other collaborative development. In addition, Frederick city and county officials highlighted partnership... View Post


Wednesday, May 3, 2017

Nanomedicine Award 2017

The European Technology Platform for Nanomedicine (ETPN) and the EU-funded consortium ENATRANS have launched the third edition of the Nanomedicine Award to honor the best international nanomedicine innovations for 2017.

The goal of the Award is to promote and reward two excellent innovative nanomedicine-based solutions that could bring significant benefits to patients, answering unmet... View Post


Wednesday, May 3, 2017

New Innovative Research in Cancer Nanotechnology (IRCN) Funding Opportunity Announcement (R01)

NCI’s Office of Cancer Nanotechnology Research has published a new funding opportunity announcement (FOA) for the Innovative Research in Cancer Nanotechnology (IRCN) initiative, PAR-17-240. All IRCN awards made through this announcement are R01 grants and will be part of the Alliance for Nanotechnology in Cancer network. Due dates are twice per year, with the announcement remaining open until... View Post


Tuesday, April 4, 2017

2017 FNLCR Technology Showcase

The Frederick National Laboratory for Cancer Research (FNLCR) will be hosting a half-day event that will showcase technologies being developed at the National Cancer Institute (NCI) and FNLCR. The event aims to introduce the Frederick community to the regional technology development stakeholders, highlight available resources, as well as to encourage startup company formation, technology... View Post


Wednesday, March 15, 2017

Video Overview of NCL Services

Not sure what the NCL does or how we might work together? Watch the NCL’s overview video to learn more about the services we offer.

Learn more about NCL’s free characterization service for cancer nanomedicines and the types of fee-based services we provide. Contact us with any questions. A staff member will be happy to answer... View Post


Friday, March 3, 2017

Equivalence of Complex Drug Products: Scientific and Regulatory Challenges

Missed the NYAS meeting on “Equivalence of Complex Drug Products: Scientific and Regulatory Challenges”? The academy has just published an e-briefing from the meeting. Here you will be able to find notes from the meeting, as well as videos of select presentations. You can also find links to related publications and websites.

The meeting was co-organized by the Non Biological... View Post


Thursday, February 2, 2017

Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions.

The first issue of ACS Nano for 2017 features an article on the “Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions.” The article, co-authored by NCL’s Senior Immunologist, Marina Dobrovolskaia, along with several other well-known names in the field, summarizes the topics of discussion from a recent meeting on the subject. The two-day workshop was held... View Post


Tuesday, December 6, 2016

Nature Reviews Materials

NCL’s Director, Scott McNeil, recently published a Correspondence article in Nature Reviews Materials. “Evaluation of nanomedicines: Stick to the basics”, was written in response to another recent Nature Reviews Materials article, Wilhelm, et al, Nature Reviews Materials, 2016, 1, 16014. The Wilhelm, et al. article provides a retrospective analysis of nanoparticle drug... View Post


Tuesday, December 6, 2016

Join our LinkedIn group on Nanomedicine Preclinical Development

NCL has created a focus group on LinkedIn, designed to connect researchers within the nanotech field. The aim of the group will be to discuss the latest news, trends, and issues of Nanomedicine Preclinical Development.

Join here: https://www.linkedin.com/groups/8555666


Pages